Patent · US Active

Advanced drug development and manufacturing

US10877035B2 · kind B2 · utility

1Cited by

16References

18Claims

0Family size

Assignee

Icagen, LLC · US

Inventors

Eva R. Birnbaum · Los Alamos, US
Andrew T. Koppisch · Flagstaff, US
Sharon M. Baldwin · Santa Fe, US
Benjamin P. Warner · Los Alamos, US
T. Mark McCleskey · Los Alamos, US
Jennifer A. Berger · Los Alamos, US
Jeffrey J. Stewart · Cary, US
Michael N. Harris · Los Alamos, US
Anthony K. Burrell · Los Alamos, US

Key dates

Filing date	Apr 22, 2015
Grant date	Dec 29, 2020
Priority date	—
Expiry date	Jul 14, 2036

Classification

Technology area (CPC G)Physics
CPC primaryG01N2500/04
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

X-ray fluorescence (XRF) spectrometry has been used for detecting binding events and measuring binding selectivities between chemicals and receptors. XRF may also be used for estimating the therapeutic index of a chemical. For estimating the binding selectivities of a chemical versus chemical analogs, for measuring post translational modification of proteins, and for drug manufacturing.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.